Allergy Therapeutics (LON:AGY) Reaches New 1-Year Low – Should You Sell?

Allergy Therapeutics plc (LON:AGY) shares reached a new 52-week low on Monday . The company traded as low as GBX 6.50 and last traded at GBX 7, with a volume of 68370 shares trading hands. The stock had previously closed at GBX 7.

Allergy Therapeutics Price Performance

The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The stock has a market cap of £443.28 million, a PE ratio of -7.22, a P/E/G ratio of -30.70 and a beta of 0.85. The company’s 50 day moving average is GBX 9.21 and its 200-day moving average is GBX 10.39.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. The firm had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. As a group, sell-side analysts predict that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.